Accura has advised EQT on the acquisition of Fertin Pharma A/S (“Fertin”), the world’s largest B2B manufacturer of medicated chewing gum having nicotine gum (Nicotine Replacement Therapy – NRT) as their largest product category. Fertin also develops other medicated chewing gum products.
Fertin employs 715 people and was founded by the Bagger-Sørensen family. The 2016 annual revenue is estimated at DKK 851m.
The Bagger-Sørensen family will reinvest and enter a partnership with EQT to continue the development of Fertin and accelerate growth in the company.
Accura advised EQT.